Radiation oncology firm Elekta has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Response automatic gating technology for prostate cancer.
The firm's Clarity 4D prostate monitoring system can now automatically interrupt, or "gate," the radiation beam when it detects that the prostate has moved out of position. The clearance will allow physicians to safeguard the patient's normal tissues from overexposure to radiation during prostate radiotherapy.
The interface is available as an option with Elekta's Versa HD radiation therapy treatment system, the firm said.
